Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 1, 2020SHILAP Revista de lepidopterologíaOpen Access

Alzheimer's disease drug development pipeline: 2020

View Full Paper
Ask AI
Bookmark
Share

Authors

JCJeffrey L. CummingsGLGaram LeeARAaron Ritter

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Cummings et al. (2020) studied this question.

synapsesocial.com/papers/69db236d0d8d6ef495a3d0a7https://doi.org/10.1002/trc2.12050
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Effect of Citalopram on Agitation in Alzheimer Disease2014 · 573 citations
  2. 2Discovering New Treatments for Alzheimer's Disease by Repurposing Approved Medications2013 · 82 citations
  3. 3Globalization of Alzheimer's disease clinical trials2011 · 37 citations
  4. 4The Alzheimer's Prevention Initiative Autosomal‐Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal‐dominant Alzheimer's disease, including a placebo‐treated noncarrier cohort2018 · 130 citations
  5. 5Pimavanserin: Potential Treatment For Dementia-Related Psychosis2018 · 86 citations